Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-08
2011-03-08
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S004300
Reexamination Certificate
active
07902147
ABSTRACT:
Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one APOE4 allele in the subject, the presence of an APOE4 allele identifying the subject as responsive to the treatment. Also provided are methods of treating a subject afflicted with chronic lymphocytic leukemia, including administering an estrogenic agent, an androgen withdrawal agent, an apoE4 peptide or mimetic thereof, and/or a chemotherapeutic agent in an amount effective to treat said chronic lymphocytic leukemia. Methods of determining a prognosis for a patient diagnosed with chronic lymphocytic leukemia are also provided. In addition, methods for stratifying a subject into a subgroup of a clinical trial and methods for identifying a patient in a clinical trial of a treatment for chronic lymphocytic leukemia are herein provided.
REFERENCES:
patent: 5288717 (1994-02-01), Raveendranath et al.
patent: 5422119 (1995-06-01), Casper
patent: 5508167 (1996-04-01), Roses et al.
patent: 5716828 (1998-02-01), Roses et al.
patent: 5723455 (1998-03-01), Tanabe et al.
patent: 5767248 (1998-06-01), Roses et al.
patent: 6027896 (2000-02-01), Roses et al.
patent: 6251587 (2001-06-01), Sévigney et al.
patent: 6432643 (2002-08-01), Einstein et al.
patent: 6828103 (2004-12-01), Herrington et al.
patent: 6896885 (2005-05-01), Hanna
patent: 7049078 (2006-05-01), Poirier
patent: 7138426 (2006-11-01), DiNinno et al.
patent: RE39419 (2006-12-01), Day et al.
patent: 7208481 (2007-04-01), Phan et al.
patent: 7220833 (2007-05-01), Nelson et al.
DeKroon et al, J Lipid Res, 2003, 44:1566-1573.
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4.
Dermer, Bio/Technology, 1994, 12:320.
Gura (Science, 1997, 278:1041-1042.
Johnson and Tracey, ‘Peptide and Protein Drug Delivery’, In: Encyclopedia of Controlled Drug Delivery, vol. 2, 1999, pp. 816-833.
Narasimhan P and Amaral L. Lymphopenic response of patients presenting with chronic lymphocytic leukemia associated with carcinoma of the prostate to diethylstilbestrol: correlation of response to the in vitro synthesis of rna by patient lymphocytes and its relationship to transcortin. American Journal of Hematology. 1980; 8(4): 369-375. Abstract only.
Rosen St et al. Estrogen receptor analysis in chronic lymphocytic leukemia. Blood. Nov. 1983; 62(5): 996-999.
Dallongeville J et al. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. Journal of Lipid Research. 1992; 33: 447-454.
Huang P et al. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. Sep. 21, 2000; 407: 390-395.
Gruber CJ et al. Production and actions of estrogens. The New England Journal of Medicine. Jan. 31, 2002; 346(5): 340-352.
Raber J et al. Androgens protects against apolipoprotein E4-induced cognitive deficits. The Journal of Neuroscience. Jun. 15, 2002; 22(12): 5204-5209.
Dekroon RM et al. ApoE genotype-specific inhibition of apoptosis. Journal of Lipid Research. 2003; 44: 1566-1573.
Cuní S et al. A sustained activation of P13K/NF-\B pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004; 18: 1391-1400.
Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leukemia & Lymphoma. Feb. 2004; 45(2): 205-219.
Chiorazzi N et al. Chronic lymphocytic leukemia. The New England Journal of Medicine. Feb. 24, 2005; 352(8): 804-815.
Gao N et al. 2-methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene. 2005; 24: 3797-3809.
Danilov AV et al. Molecular pathogenesis of chronic lymphocytic leukemia. Current Molecular Medicine. 2006; 6(6): 665-675.
Dekroon R et al. APOE-4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/akt pathway via the phosphoinositol phosphatase SHIP2. Circulation Research. Oct. 13, 2006; 829-836.
Wang JM et al. Activation of estrogen receptor α increases and estrogen receptor β decreases apoliprotein E expression in hippocampus in vitro and in vivo. PNAS. Nov. 7, 2006; 103(45): 169984-169988.
Weinberg JB et al. Apolipoprotein E (APOE) genotype as a determinant of survival in women with chronic lymphocytic leukemia. Blood (American Society of Hematology Annual Meeting Abstracts). 2007; 110: Abstract 3081.
Weinberg JB et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. American Journal of Hematology. 2007: 1063-1070.
Weinberg JB et al. Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. Leukemia. Leukemia. 2008; 1-9.
Strittmatter Warren J.
Weinberg J. Brice
Duke University
Halvorson Mark
Myers Bigel Sibley & Sajovec P.A.
Yu Misook
LandOfFree
Chronic lymphocytic leukemia prognosis and treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chronic lymphocytic leukemia prognosis and treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chronic lymphocytic leukemia prognosis and treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2620985